LB Pharma to host in-person, virtual R&D Day spotlighting LB-102 schizophrenia program

Bitget2026/10/06 12:07

LB Pharmaceuticals will host an in-person and virtual R&D Day on Oct. 27, 2026, starting at 2:00 p.m. ET. Program will highlight development of LB-102 in schizophrenia, ahead of a planned topline Phase 3 readout in H1 2027. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LB Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060800PRIMZONEFULLFEED9839941) on October 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.